Svein Dueland
- Oncology top 0.5%
- Surgery top 1%
- Hepatology top 0.5%
- Epidemiology top 2%
- Molecular Biology top 10%
- Co-authors
- Pål‐Dag LineMorten HagnessAksel FossMarianne G. GurenKjersti FlatmarkHarald GrutRoger J. DavisSteinar Aamdal
- Topics
- Hepatocellular Carcinoma Treatment and Prognosis (49 papers)Colorectal Cancer Treatments and Studies (38 papers)Cholangiocarcinoma and Gallbladder Cancer Studies (33 papers)
- Cited by
- HepatologyOncologyTransplantation
- Journals
- Proceedings of the National Academy of SciencesJournal of Biological ChemistryJournal of Clinical Oncology
- Partner nations
- NorwayUnited StatesDenmark
In The Last Decade
Svein Dueland
168 papers receiving 5.4k citations
Hit Papers
Peers
Comparison fields: 5 of 121
- Oncology 2.9k
- Surgery 2.1k
- Hepatology 1.4k
- Epidemiology 1.2k
- Molecular Biology 1.0k
Countries citing papers authored by Svein Dueland
This map shows the geographic impact of Svein Dueland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Svein Dueland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Svein Dueland more than expected).
Fields of papers citing papers by Svein Dueland
This network shows the impact of papers produced by Svein Dueland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Svein Dueland. The network helps show where Svein Dueland may publish in the future.
Co-authorship network of co-authors of Svein Dueland
This figure shows the co-authorship network connecting the top 25 collaborators of Svein Dueland. A scholar is included among the top collaborators of Svein Dueland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Svein Dueland. Svein Dueland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 0 | |
| 3 | 9 | |
| 4 | 36 | |
| 5 | 4 | |
| 6 | 8 | |
| 7 | 20 | |
| 8 | 40 | |
| 9 | 3 | |
| 10 | 4 | |
| 11 | 2 | |
| 12 | 28 | |
| 13 | Ki-67 Proliferative Index Predicts Response to Chemotherapy and Survival in 252 Patients with High-Grade Gastrointestinal Neuroendocrine Carcinoma (WHO G3) | 2 |
| 14 | 244 | |
| 15 | 92 | |
| 16 | 14 | |
| 17 | 27 | |
| 18 | Pharmacokinetics of a nucleoside analogue CP-4055 in two phase I trials using a daily for 5 days schedule and three intermittent weekly or biweekly schedules | 2 |
| 19 | 44 | |
| 20 | 55 |
About Svein Dueland
Svein Dueland is a scholar working on Hepatology, Oncology and Transplantation, having authored 173 papers that have together received 5.5k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (49 papers), Colorectal Cancer Treatments and Studies (38 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (33 papers). The work is most often cited by research in Hepatology (1.4k citations), Oncology (2.9k citations) and Transplantation (206 citations). Svein Dueland has collaborated with scholars based in Norway, United States and Denmark. Frequent co-authors include Pål‐Dag Line, Morten Hagness, Aksel Foss, Marianne G. Guren, Kjersti Flatmark, Harald Grut, Roger J. Davis, Steinar Aamdal, Trygve Syversveen and Stein Gunnar Larsen. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.